357. Deputy Cormac Devlin asked the Minister for Health the number of outstanding legal actions involving a medication (details supplied) and associated costs paid from 2018 to 1 July 2026. [66063/26]
Parliamentary questions
Questions
TDs ask ministers questions to get answers on the record, most of them in writing. Here is every one asked in the 34th Dáil, by the department it went to and the subject heading it was filed under. How questions work
Browse the questions
Showing questions asked by Cormac Devlin under the heading Medicinal Products.
14 questions match, newest first.
1278. Deputy Cormac Devlin asked the Minister for Health if she will provide an update on the NCPE appraisal of ritlecitinib (litfulo) for severe alopecia areata, including current stage, any ongoing HSE pricing and reimbursement engagement with the applicant, expected timelines for a decision, and proposed prescribing setting if approved (details supplied); and if she will make a statement on the matter. [30914/26]
1279. Deputy Cormac Devlin asked the Minister for Health if an application has been received by the HSE for pricing and reimbursement of baricitinib for the alopecia areata indication; if not, whether the HSE or her Department has engaged with the marketing authorisation holder regarding a submission (details supplied); and if she will make a statement on the matter. [30915/26]
1280. Deputy Cormac Devlin asked the Minister for Health whether her Department, the HSE or the HPRA has engaged with the manufacturer of deuruxolitinib (leqselvi) regarding plans for EU submission and availability in Ireland; whether any named-patient or compassionate access requests have been received (details supplied); and if she will make a statement on the matter. [30916/26]
1281. Deputy Cormac Devlin asked the Minister for Health if she will outline whether JAK inhibitor treatments for severe alopecia areata, where reimbursed, will be provided via the High Tech Arrangement; the intended initiation and monitoring setting; the proposed stop rules; the estimated annual budget impact and eligible patient numbers (details supplied); and if she will make a statement on the matter. [30917/26]
1282. Deputy Cormac Devlin asked the Minister for Health the number of patients treated for alopecia areata with JAK inhibitors in public hospitals in each of the past three years, by CHO and by medicine, including any named-patient access, and associated monitoring protocols; and if she will make a statement on the matter. [30918/26]
665. Deputy Cormac Devlin asked the Minister for Health to report on the engagement to date between her Department, the HSE and the manufacturer of the Omnipod 5 tubeless hybrid closed-loop insulin delivery system regarding its introduction to the Irish market; if a pricing and reimbursement application has been submitted under the Health (Pricing and Supply of Medical Goods) Act 2013; and if she will make a statemen…
666. Deputy Cormac Devlin asked the Minister for Health if the HSE, NCPE or her Department have undertaken, or plan to undertake, a clinical and cost-effectiveness assessment of the Omnipod 5 tubeless hybrid closed-loop insulin pump system, having regard to its availability and funded use in the UK and other EU member states; if so, to outline the status and expected timelines for a decision; and if she will make a s…
667. Deputy Cormac Devlin asked the Minister for Health her views on the potential role of the Omnipod 5 tubeless hybrid closed-loop insulin system in expanding patient choice for people with type 1 diabetes, including children, people with disabilities, needle or tube aversion, and those with high treatment burden; if she will request the HSE to examine its potential use within the national diabetes technology pathw…
2618. Deputy Cormac Devlin asked the Minister for Health if she will provide an update on the NCPE appraisal of ritlecitinib (litfulo) for severe alopecia areata, including current stage, any ongoing HSE pricing and reimbursement engagement with the applicant; the expected timelines for a decision and proposed prescribing setting if approved; and if she will make a statement on the matter. [46999/25]
2619. Deputy Cormac Devlin asked the Minister for Health if an application has been received by the HSE for pricing and reimbursement of baricitinib for the alopecia areata indication; if not, if the HSE or her Department has engaged with the marketing authorisation holder regarding a submission; and if she will make a statement on the matter. [47000/25]
2620. Deputy Cormac Devlin asked the Minister for Health if her Department, the HSE or the HPRA has engaged with the manufacturer of deuruxolitinib (leqselvi) regarding plans for EU submission and availability in Ireland; if any named-patient or compassionate access requests have been received; and if she will make a statement on the matter. [47001/25]
2646. Deputy Cormac Devlin asked the Minister for Health the current days of cover for the top 100 essential medicines, by category; the medicines experiencing repeated shortages since 2023; the plan to establish a rotating national reserve and domestic fill finish capacity; and if she will make a statement on the matter. [47208/25]
870. Deputy Cormac Devlin asked the Minister for Health the status of consideration, use (even on a trial basis), and funding for the drug givinostat for Duchenne muscular dystrophy; and if she will make a statement on the matter. [32461/25]